Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature

Background: The introduction of checkpoint inhibitors is a long-awaited new option for a urothelial cancer with a poor prognosis. Apart from clinical studies, the data on real world experience is scarce.Methods: Patients for monotherapy with either Atezolizumab, Nivolumab or Pembrolizumab after chem...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Christian Fuhrmann, Julian P. Struck, Philipp Ivanyi, Mario W. Kramer, Marie C. Hupe, Bennet Hensen, Alexander Fürschke, Inga Peters, Axel S. Merseburger, Markus A. Kuczyk, Christoph-A. J. von Klot
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020-05-01
Colecção:Frontiers in Oncology
Assuntos:
metastatic urothelial carcinoma
checkpoint inhibition
immunotherapy
atezolizumab
pembrolizumab
nivolumab
Acesso em linha:https://www.frontiersin.org/article/10.3389/fonc.2020.00808/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados